corticotropin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4931 9002-60-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • corticotropin
  • ACTH
  • corticotrophin
  • adrenocorticotrophic hormone
  • acthar gel
  • cortrophin
  • corticotropin zinc hydroxide
  • corticotropin-zinc hydroxide
  • cortrophin-zinc
A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.
  • Molecular weight: 4541.14
  • Formula: C207H308N56O58S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 114
  • HDO: 63
  • TPSA: 1836.25
  • ALOGS:
  • ROTB: 145

Drug dosage:

DoseUnitRoute
25 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 3, 1950 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 104.72 19.59 63 5550 42901 50556610
Injection site bruising 92.40 19.59 55 5558 36713 50562798
Product dose omission issue 72.08 19.59 95 5518 183743 50415768
Therapy cessation 55.33 19.59 35 5578 25976 50573535
Swelling face 50.87 19.59 44 5569 52551 50546960
Blood glucose increased 50.26 19.59 50 5563 71274 50528237
Epidural lipomatosis 43.69 19.59 8 5605 105 50599406
Weight increased 43.28 19.59 79 5534 201812 50397699
Fluid retention 42.28 19.59 39 5574 50610 50548901
Infantile spasms 38.67 19.59 8 5605 204 50599307
Magnetic resonance imaging head abnormal 37.52 19.59 12 5601 1765 50597746
Cushingoid 37.11 19.59 17 5596 6628 50592883
Insomnia 35.66 19.59 67 5546 174798 50424713
Injection site discolouration 30.26 19.59 15 5598 6959 50592552
COVID-19 29.73 19.59 31 5582 46631 50552880
Visual impairment 26.22 19.59 35 5578 68240 50531271
Peripheral swelling 24.93 19.59 64 5549 205872 50393639
Irritability 23.92 19.59 22 5591 28404 50571107
Nail pigmentation 22.42 19.59 5 5608 183 50599328
Increased appetite 22.27 19.59 13 5600 8348 50591163
Appetite disorder 20.34 19.59 11 5602 6103 50593408

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infantile spasms 56.82 27.99 10 1958 179 29572380
Fluid retention 45.94 27.99 25 1943 23535 29549024
Blood glucose increased 39.27 27.99 32 1936 58952 29513607
Irritability 39.05 27.99 22 1946 22130 29550429
Multiple-drug resistance 38.18 27.99 13 1955 3887 29568672
Weight increased 37.73 27.99 35 1933 76632 29495927
Insomnia 35.21 27.99 36 1932 88725 29483834
Drug ineffective 32.49 27.99 73 1895 363097 29209462
Intramyelinic oedema 31.70 27.99 4 1964 4 29572555
Swelling 29.67 27.99 22 1946 35261 29537298

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site bruising 92.91 23.25 50 5380 36323 64456979
Product dose omission issue 73.38 23.25 86 5344 194661 64298641
Multiple sclerosis relapse 71.46 23.25 44 5386 41091 64452211
Blood glucose increased 67.51 23.25 60 5370 98013 64395289
Therapy cessation 67.49 23.25 39 5391 32450 64460852
Insomnia 56.35 23.25 76 5354 197760 64295542
Fluid retention 52.38 23.25 42 5388 59564 64433738
Irritability 48.29 23.25 33 5397 36713 64456589
Weight increased 46.20 23.25 72 5358 213276 64280026
Cushingoid 46.09 23.25 19 5411 7584 64485718
Infantile spasms 44.44 23.25 9 5421 274 64493028
Swelling face 40.27 23.25 36 5394 59130 64434172
Magnetic resonance imaging head abnormal 37.17 23.25 12 5418 2400 64490902
Intramyelinic oedema 30.29 23.25 4 5426 5 64493297
Peripheral swelling 30.11 23.25 59 5371 209094 64284208
Epidural lipomatosis 29.56 23.25 8 5422 869 64492433
Multiple-drug resistance 28.74 23.25 13 5417 6489 64486813
Drug ineffective 28.17 23.25 142 5288 840105 63653197
Hypertension 26.84 23.25 64 5366 259197 64234105
Visual impairment 26.63 23.25 32 5398 74045 64419257
Increased appetite 26.02 23.25 14 5416 10132 64483170

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01AA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
ACTH
FDA CS M0000499 Adrenocorticotropic Hormone
CHEBI has role CHEBI:33295 diagnostic aid
FDA EPC N0000175941 Adrenocorticotropic Hormone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
West syndrome indication 28055006
Stevens-Johnson syndrome indication 73442001 DOID:0050426
Exacerbation of multiple sclerosis indication 192929006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication
Cattle Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication
Cattle Primary bovine ketosis Indication
Dogs Diagnostic aid to test for adrenal dysfunction Indication
Dogs Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication

🐶 Veterinary products

ProductApplicantIngredients
Adrenomone Dechra, Ltd. 1
ACTH Gel Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.37 acidic
pKa3 3.62 acidic
pKa4 3.86 acidic
pKa5 4.07 acidic
pKa6 4.31 acidic
pKa7 4.6 acidic
pKa8 9.43 acidic
pKa9 10.05 acidic
pKa10 12.25 acidic
pKa11 12.36 acidic
pKa12 12.63 acidic
pKa13 12.69 acidic
pKa14 12.93 acidic
pKa15 13.11 acidic
pKa16 13.11 acidic
pKa17 13.22 acidic
pKa18 13.41 acidic
pKa19 13.55 acidic
pKa20 13.6 acidic
pKa21 13.66 acidic
pKa22 13.75 acidic
pKa23 13.76 acidic
pKa24 13.79 acidic
pKa25 13.89 acidic
pKa26 14.0 acidic
pKa27 11.5 Basic
pKa28 11.26 Basic
pKa29 11.01 Basic
pKa30 10.81 Basic
pKa31 10.55 Basic
pKa32 10.3 Basic
pKa33 9.94 Basic
pKa34 7.62 Basic
pKa35 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Adrenocorticotropic hormone receptor GPCR AGONIST UNKNOWN IUPHAR
Melanocortin receptor 4 GPCR AGONIST Ki 6.16 IUPHAR
Melanocortin receptor 3 GPCR AGONIST Ki 7.06 IUPHAR
Melanocyte-stimulating hormone receptor GPCR AGONIST Ki 8.60 IUPHAR
Adrenocorticotropic hormone receptor GPCR AGONIST Kd 9.80 IUPHAR

External reference:

IDSource
D00146 KEGG_DRUG
4018523 VUID
N0000146845 NUI
4018523 VANDF
4022410 VANDF
CHEBI:3892 CHEBI
CHEMBL1201610 ChEMBL_ID
3633 IUPHAR_LIGAND_ID
1366 INN_ID
9050-75-3 SECONDARY_CAS_RN
DB01285 DRUGBANK_ID
K0U68Q2TXA UNII
16132265 PUBCHEM_CID
2584471 RXNORM
2492 MMSL
326050 MMSL
4506 MMSL
4507 MMSL
84 MMSL
d00604 MMSL
002113 NDDF
002114 NDDF
126187000 SNOMEDCT_US
40789008 SNOMEDCT_US
C0001655 UMLSCUI
CHEMBL1201609 ChEMBL_ID
471 INN_ID
12427-33-7 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
1 Detoxification HUMAN OTC DRUG LABEL 81 55146-011 LIQUID 30 [hp_C] ORAL unapproved homeopathic 9 sections
Purified Cortrophin Gel HUMAN PRESCRIPTION DRUG LABEL 1 62559-860 INJECTION 80 [USPU] INTRAMUSCULAR NDA 14 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8710 INJECTION 80 [USPU] INTRAMUSCULAR NDA 27 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8710 INJECTION 80 [USPU] INTRAMUSCULAR NDA 27 sections